Triple threat: rapid detection and differentiation of SARS-CoV-2, Flu, and RSV
COVID-19, influenza (flu), and respiratory syncytial virus (RSV) are 3 major viral respiratory infections that will be tested for in your laboratory and are difficult to differentiate from one another without diagnostic testing.1,2
Co-infection with SARS-CoV-2 and other viral respiratory pathogens is not rare and increases disease severity and mortality risk compared to SARS-CoV-2 mono-infection.3,4
The WHO reports that the EG.5 variant has shown increased prevalence.5
As well, the CDC say that the BA.2.86 variant's mutations may challenge immunity provided by COVID-19 vaccines and/or previous infection.6
Influenza is not the only disease to tackle this season. RSV has been increasingly recognized as an important public health concern as it is responsible for more respiratory complications and casualties than COVID-19 or influenza in children.
RSV may be responsible for:
- 3.2 million hospitalisations and 118,200 deaths in children younger than 5 years old.7
- Exacerbation of pre-existing respiratory conditions in adults
- Serious respiratory illness in the elderly
- Bronchiolitis in infants and children, pneumonia in children and adults, and acute bronchitis in adults.8
With many overlapping signs and symptoms across respiratory diseases, clinicians will face challenges in obtaining the accurate differentiation required for timely treatment.
Do you have effective differential diagnostic testing in place to reduce the inevitable transmission of respiratory tract infections (RTIs)?
Use the BD Respiratory Viral Panel for BD MAX™ System: get 4 results from 1 specimen in a single run
Can you guarantee sufficient assay sensitivity in your laboratory to tackle the mass of seasonal pathogens we are facing?
With new recommendations from the European Centre for Disease Prevention and Control to urgently develop and sustain resilient, population based, integrated surveillance systems for influenza, COVID-19 and potentially other respiratory virus infections, the time is right to reliably equip your lab for accurate detection and differentiation of winter respiratory viruses and their variants.9
The BD Respiratory Viral Panel for BD MAX™ System can simultaneously detect and differentiate SARS-CoV-2, flu A, flu B, and RSV in a single nasal or nasopharyngeal swab sample.9
With the BD Respiratory Viral Panel, you can be confident in detecting the SARS-CoV-2 virus, including new variants like EG.5 and BA.2.86.
Don't let your workflow efficiency succumb to the pressures of unprecedented volumes of testing.
The BD Respiratory Viral Panel for BD MAX™ System provides rapid and accurate detection in a single run and, with the co-testing method, helps to increase capacity and speed of diagnostics during the busy influenza season.
*Product availability may vary in different countries; please contact your local BD representative.
Consolidate your molecular testing to the BD MAX™ System and discover new respiratory assays
Extended respiratory menu on the BD MAX™ System
Greater versatility with new respiratory assays on the BD MAX™ System
VIASURE Pneumocystis jirovecii Real Time PCR Detection Kit for BD MAX™ System
Test for the cause of Pneumocystis pneumonia with the BD MAX™ System
VIASURE Bordetella Real Time PCR Detection Kit for BD MAX™ System*
Detect and differentiate between three Bordetella species
The innovation of the BD MAX™ System offers you a fully integrated, automated real-time PCR benchtop platform with the possibility of running simultaneously its broad menu of molecular in vitro diagnostics (IVDs) and open-system tests.**
- Less than 1.5 minutes hands-on time per sample10,11
- 24 patient results in an average of 2.5 hours11
- 96 samples per 8-hour shift11
Its automated workflow reduces manual tasks to achieve rapid, reliable results and facilitates off-hour testing, helping to offset molecular testing costs.***10,12
